Pipeline
Licensing & BD
Clinical Trials
Careers
About Us
Back
Home
Our drug development pipeline
Contact us
Drugs currently under development
TrialSpark drugs in the news
PR Newswire
TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio
November 29, 2022
PR Newswire
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck and forms NewCo
January 10, 2022
BioMed Central
Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis
April 9, 2021
Close